Sinopharm's (HKG:1099) attributable profit rose to 1.46 billion yuan in the first quarter from 1.42 billion yuan in the year-ago period, according to a Monday filing with the Hong Kong bourse.
Earnings per share at the drug company increased to 0.47 yuan from 0.46 yuan in the previous year.
Operating revenue declined to 141.7 billion yuan from 147.3 billion yuan in the prior-year period.